ClinicalTrials.gg
TerminatedNCT02561832Updated Feb 20, 2019Results posted

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

A Phase 1 interventional study of Olaparib and Carboplatin in Breast Cancer, sponsored by AstraZeneca. Terminated at 7 sites in 2 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2019-02-20.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Why this study was terminated
This decision was based upon strategic considerations impacting the clinical development of olaparib in this indication.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing olaparib in Breast Neoplasms — 11 open to participants now, 25 under way, 4 of them phase 3. olaparib · Breast Neoplasms.

Enrollment
39th of 51
15 · median 54
Started
2015
with 1 other
Phase 1
16 of 51
1 open now
Registered
14th of 51
by date
Lead sponsor
11 of 51
AstraZeneca

Among the 51 studies testing olaparib in Breast Neoplasms, this one is the 39th largest by enrollment, is one of 2 that started in 2015, is one of 16 in phase 1, and was the 14th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 51 studies testing olaparib in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing olaparib in Breast Neoplasms, or all of them as a file.
02

Study summary

This is an open-label study to assess the safety, tolerability and efficacy of olaparib in combination with carboplatin. There are two parts in this study: Part A, a dose escalation in patients with advanced Human Epidermal Growth Factor 2 (HER-2) negative breast cancer and Part B, a dose expansion in the neoadjuvant treatment of HER-2 negative breast cancer patients with germline Breast Cancer Susceptibility Gene (BRCA)1/2 mutations.

Read the detailed description

In Part A up to 36 evaluable patients with advanced breast cancer will be enrolled across 6 cohorts. The total number of patients will depend on the number of dose escalations necessary to enable a decision to be made on the recommended dose to take forward into Part B of the study.

The planned dose escalation will start with cohort 1, where patients will receive carboplatin (AUC5) on day 1 of cycle 1, and will start dosing with olaparib tablets at the dose of 50 mg twice daily (bd) on day 4 until day 19 of cycle 1 inclusive (a total of 16 days per cycle). Patients will receive carboplatin on day 1 of each 3 weeks cycle in combination with olaparib for a total of 4 cycles. Provided that there are no safety concerns after assessment of 6 evaluable patients in the first cohort, patients in subsequent cohorts may be dosed following Safety Review Committee (SRC) approval. Dose escalation scheme may be adjusted during the study on the basis of emerging safety, efficacy and pharmacokinetic data. Those patients in Part A who tolerate the combination up to and including cycle 4 may remain on treatment, either continuing with the combination, with carboplatin alone at the same AUC or with olaparib alone at the dose of 300 mg bd, if in the opinion of the treating Investigator, a patient is deemed to be deriving clinical benefit from treatment. In these cases, a patient may remain on treatment until progression, unacceptable toxicity or until other discontinuation criteria are met. Beyond cycle 4, patients will undergo assessments in line with the clinical protocol. Once the maximum tolerated dose (MTD) and/or recommended dose (RD) has been defined in Part A, a dose expansion phase, Part B will begin and this will include up to 21 patients with HER2 negative breast cancer, with a deleterious or suspected deleterious germlineBRCA1/2 (gBRCA1/2) mutation, who are deemed eligible for neoadjuvant therapy.

Part B will explore the safety, tolerability and efficacy of the combination of olaparib and carboplatin in terms of pathological complete response (pCR) rate. Neoadjuvant systemic therapy will consist of the following anti-cancer drugs for a total of 8 cycles of treatment:

  • The first 4 cycles (cycle 1 to cycle 4: 12 weeks) will be based on combination of olaparib, at the defined RD and schedule from Part A, with carboplatin. It is expected that a cycle of treatment would be 3 weeks.
  • Another 4 cycles (cycle 5 to cycle 8) will be based on a combination of an anthracycline and cyclophosphamide (AC). The choice of the AC regimen will be up to local Investigator following international guidelines (National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), and St Gallen).

The tumour response will be assessed through careful clinical examination and also with radiological examinations between cycle 4 and 5 and at the end of neoadjuvant part, before surgery. Additionally, tumour biopsy will be performed within 7 days before cycle 5 day 1, after completion of carboplatin and olaparib combination therapy and early pathological response assessed by local pathologist. Curative-intent surgery should be performed following completion of neoadjuvant treatment in all patients, 3 to 5 weeks after day 1 of the last cycle of neoadjuvant treatment.

A decision has been made to stop recruitment after Part A cohort 2, and to not start Part B of the study. The protocol has been amended to define that the collection of clinical data will stop once the final patient from cohort 2 of Part A has completed 4 cycles or all patients from cohort 2 of Part A discontinue prior to end of cycle 4 to enable data analysis and reporting. The database would close at this time point, however AstraZeneca commits to providing study treatment to ongoing patients that continue to receive clinical benefit, in Investigator's judgment. Patients who remain on study treatment after this time point will be monitored according to routine clinical practice as defined by the Investigator and no clinical data will be collected, other than SAEs and drug dispensing/accountability.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • breast cancer
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria

  • Male or female aged ≥18 years
  • Normal organ and bone marrow function, measured within 28 days prior to administration of study treatment
  • performance status of 0-1
  • or evidence of non-childbearing status for women of .

Additional for patients participating in Part A only

  • Advanced or breast cancer that is negative (HR positive or HR negative)
  • Between 0 and 2 lines of prior cytotoxic chemotherapy. Additional for patients participating in Part B only
  • Patients with operable breast adenocarcinoma and no evidence of metastatic disease are allowed.
  • Patient must meet at least one of the following criteria: Clinical primary tumour size defined as T2 or above, clinical or patho-histological evidence of regional lymph nodes involvement (N+), grade 2-3 disease
  • Availability of formalin fixed, paraffin embedded tumour sample from diagnostic (Not Applicable for patients at sites in Israel)
  • Histological confirmation of HER-2 negative breast cancer
  • Documented germline mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious
  • Eligible for chemotherapy, but have not yet received neoadjuvant chemotherapy for breast cancer (chemo-naive) Exclusion criteria
  • Exposure to an product within 30 days or 5 half-lives (whichever is the longer) prior to enrolment
  • Prior use of Poly ADP Ribose Polymerase (PARP) inhibitors
  • Patients with a known to olaparib or carboplatin
  • Concurrent treatment with an ovarian hormonal replacement therapy or with hormonal agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator. Patient must have discontinued use of such agents 3 weeks prior to beginning study treatment. Luteinising hormone-Releasing hormone (LHRH) analogues are allowed for all patients in Part A.
  • Concomitant use of known potent Cytochrome P450 3A4 () inhibitors and inducers
  • Persistent toxicities (Common Terminology Criteria for Adverse Event () grade ≥2 and neuropathy CTCAE > grade 1) caused by previous cancer therapy, excluding alopecia - Patient with myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) or with features suggestive of MDS/AML
  • Patient must have recovered from any effects of any major surgery
  • Patient considered at poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled seizures or active uncontrolled infection
  • Patient with known active or C, or (HIV)
  • Other within the last 5 years (few exceptions apply). Additional for patients participating in Part A only
  • Prior chemotherapy within 3 weeks of study entry
  • Other anti-cancer therapy (eg, targeted biotherapy of hormonal agents) within 3 weeks of study entry
  • Radiation therapy within 4 weeks or radionuclide treatment within 6 weeks of treatment start
  • Prior use of platinum compound in the advanced or metastatic setting. Previous exposure to platinum compounds is allowed only if they were used in early adjuvant or neoadjuvant setting with relapse occurring >6 months after the last platinum administration and if there is no residual toxicity
  • Patient with a history of treated Central Nervous System (CNS) metastases are eligible, provided they meet certain protocol-specified criteria.

Additional for patients participating in Part B only

  • Prior treatment (local or systemic) of their breast tumour. Sentinel lymph node biopsy is considered as diagnostic procedure and therefore is authorized before neoadjuvant treatment in part B
  • Patients with inflammatory breast cancer or patients with inoperable locally advanced breast cancer (including T4 lesions) at the time of enrolment.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Arm 1

    Part A: ascending doses of olaparib in combination with carboplatin will be administered to investigate safety and tolerability and to define the MTD and/or RD for part B. Patients will be treated with this combination up to cycle 4, after cycle 4 they can continue with combination or monotherapy (carboplatin or olaparib). Cohorts will be started sequentially, based on SRC recommendation. Part B will start after MTD/RD identification in part A. Patients will receive olaparib and carboplatin combination for first 4 cycles (21 days per cycle), at the dose, frequency and schedule recommended from Part A. This will be followed by another 4 cycles of standard cancer therapy consisting of anthracycline and cyclophosphamide regimen. Total of 8 treatment cycles will be given before final surgery

    Drug: Olaparib · Drug: Carboplatin · Drug: Anthracycline · Drug: Cyclophosphamide

Interventions

  • tablets taken orally twice daily

  • intravenous injections on day one of each cycle

  • The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines

  • The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines

06

What researchers measure

Primary outcomes

  1. Part A: Number of Subjects Reporting Adverse Events (AEs)

    Treatment-emergent AEs (TEAEs) defined as events occurring on or after cycle 1, day 1 up to and including 30 days after last dose (approximately 114 days).

    Time frame: From day 1 cycle 1, up to and including 30 days after last dose

07

Results

Posted Feb 20, 2019
Limitations and caveats
Early termination leading to a small number of subjects analyzed (N=15).

Participant flow

Patients were screened between 06 November 2015 and 02 June 2016 at 7 medical centers in 2 countries

Participant flow — Overall Study
MilestoneCohort 1Cohort 2
Started87
Informed consent obtained87
Completed13
Not completed74
Withdrew: Withdrawal by subject11
Withdrew: Adverse event30
Withdrew: Disease progression33

Outcome measures

PrimaryPart A: Number of Subjects Reporting Adverse Events (AEs)

Treatment-emergent AEs (TEAEs) defined as events occurring on or after cycle 1, day 1 up to and including 30 days after last dose (approximately 114 days).

Time frame:
From day 1 cycle 1, up to and including 30 days after last dose
Reported as:
Number · Participants
Part A: Number of Subjects Reporting Adverse Events (AEs)
ParticipantsCohort 1Cohort 2
Part A: Number of Subjects Reporting Adverse Events (AEs)87

Adverse events

Collected over AEs, including SAEs, were collected from time of signature of informed consent throughout the Treatment period (four 3-week cycles) up to and including the 30-day Follow-up period (approximately 142 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 10/8 (0%)2/8 (25%)8/8 (100%)
Cohort 20/7 (0%)0/7 (0%)7/7 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1Cohort 2
ThrombocytopeniaBlood and lymphatic system disorders1/80/7
Femur fractureInjury, poisoning and procedural complications1/80/7
Platelet count decreasedInvestigations1/80/7
Spinal cord compressionNervous system disorders1/80/7
Most frequent other events
Showing 10 of 48
Most frequent other events
EventCohort 1Cohort 2
AnaemiaBlood and lymphatic system disorders8/83/7
NauseaGastrointestinal disorders3/84/7
NeutropeniaBlood and lymphatic system disorders4/83/7
ConstipationGastrointestinal disorders4/82/7
Platelet count decreasedInvestigations3/83/7
HeadacheNervous system disorders2/83/7
ThrombocytopeniaBlood and lymphatic system disorders3/82/7
AstheniaGeneral disorders3/82/7
FatigueGeneral disorders3/81/7
LeukopeniaBlood and lymphatic system disorders1/82/7

Baseline characteristics

Full Analysis Set (FAS)/Intention to treat (ITT): the primary statistical analysis of the efficacy of olaparib/carboplatin included all patients who signed the consent form, regardless of whether the treatment was actually received or not.

Age, Continuous
Age, Continuous(Years)Cohort 1Cohort 2Total
Mean54.1 ± 14.5747.7 ± 16.1851.1 ± 15.15
Age, Customized
Age, Customized(Participants)Cohort 1Cohort 2Total
>=18 to <33011
>=33 to <50437
>=50 to <65123
>=65314
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Total
Female8715
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1Cohort 2Total
White8715
08

Study locations

7 sites
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Stony Brook, New York 11794, United States
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Madrid, 28050, Spain
  • Research Site
    Valencia, 46010, Spain
  • Research Site
    Zaragoza, 50009, Spain
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in Sep 2016, 10 months.

Results were first posted in Feb 2019, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2015
First posted
Sep 28, 2015
StartActual
Nov 6, 2015
Primary completionActual
Sep 30, 2016
CompletionActual
Feb 1, 2017
Results first posted
Feb 20, 2019
Last update
Feb 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02561832
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 28, 2015
Start date
Nov 6, 2015
Primary completion
Sep 30, 2016
Completion
Feb 1, 2017
Results posted
Feb 20, 2019
Last update
Feb 20, 2019

Study contacts

Judith Balmana
principal investigator · Hospital Vall d'Hebron, Barcelona, Spain
Tiffany Traina
principal investigator · Memorial Sloan Kettering Cancer Center, New York, USA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Olaparib · Carboplatin

Start the discussion